{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec%2C+STI571%28Imatinib+Mesylate%29",
    "query": {
      "intervention": "Gleevec, STI571(Imatinib Mesylate)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 349,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec%2C+STI571%28Imatinib+Mesylate%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T07:09:02.416Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01490775",
      "title": "Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Phase CML"
      ],
      "interventions": [
        {
          "name": "no access to eMedonline",
          "type": "BEHAVIORAL"
        },
        {
          "name": "eMedonline access",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rex Cancer Center, Raleigh, NC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2009-04",
      "completion_date": "2015-06-30",
      "has_results": false,
      "last_update_posted_date": "2018-08-13",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01490775"
    },
    {
      "nct_id": "NCT00403156",
      "title": "Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate /Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitreous -Retina- Macula Consultants of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "51 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2006-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-31",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403156"
    },
    {
      "nct_id": "NCT02709083",
      "title": "Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia",
        "Chronic Myeloid Leukemia",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2016-10",
      "completion_date": "2018-07",
      "has_results": true,
      "last_update_posted_date": "2018-11-02",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02709083"
    },
    {
      "nct_id": "NCT01130688",
      "title": "Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Zileuton",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2010-01",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-05-27",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01130688"
    },
    {
      "nct_id": "NCT01092741",
      "title": "Late Chronic Phase Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Gleevec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2001-07",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2016-05-11",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01092741"
    },
    {
      "nct_id": "NCT02508532",
      "title": "(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors (GIST)",
        "Other Relapsed or Refractory Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Avapritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2015-08",
      "completion_date": "2021-06-03",
      "has_results": true,
      "last_update_posted_date": "2022-06-21",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 9,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02508532"
    },
    {
      "nct_id": "NCT00372567",
      "title": "Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumor"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2007-06",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2011-03-17",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 6,
      "location_summary": "Detroit, Michigan • Farmington Hills, Michigan • City of Saint Peters, Missouri + 3 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "City of Saint Peters",
          "state": "Missouri"
        },
        {
          "city": "Creve Coeur",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00372567"
    },
    {
      "nct_id": "NCT01281865",
      "title": "Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Synovial Sarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "diagnostic laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2011-01",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-10-08",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01281865"
    },
    {
      "nct_id": "NCT00446316",
      "title": "Effect of Antacids on Gleevec® in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Antacids (Mg-Al-based)",
          "type": "DRUG"
        },
        {
          "name": "Imatimib Mesylate (Gleevec®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-04",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2016-06-22",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446316"
    },
    {
      "nct_id": "NCT00684411",
      "title": "Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2008-06",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-05",
      "last_synced_at": "2026-10-06T07:09:02.416Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684411"
    }
  ]
}